Learn Why The Bull Case For ORIC Pharmaceuticals (ORIC) Could Change Following Cancer Research UK Partnership

• ORIC Pharmaceuticals reported that Cancer Research UK’s Centre for Drug Development will fund, sponsor, design, and run early development for the CIP2A-targeted therapy ORIC-259. ORIC will retain an option to reacquire rights after Phase 1/2 data, and Cancer Research UK will be eligible for later milestones and royalties.
• The partnership shifts early ORIC-259 development costs onto Cancer Research UK while keeping long term economics available to ORIC Pharmaceuticals. This could ease cash use on this asset and free more of the existing US$388m balance for prostate and lung cancer programs.
• We will now look at how ORIC Pharmaceuticals’ investment narrative could shift as Cancer Research UK assumes early ORIC-259 development funding.

Scan how ORIC Pharmaceuticals fits alongside other potential breakouts by lining it up against 20 high quality undiscovered gems with strong fundamentals that are still flying under most investors’ radar.

ORIC Pharmaceuticals Investment Narrative Recap

To own ORIC Pharmaceuticals, you need to believe its lead prostate and lung cancer programs can eventually convert current clinical signals into approved therapies, despite the firm having no revenue today and ongoing losses of US$140.4m. The Cancer Research UK deal does not change those core near term drivers, but it does shift some early pipeline spend off ORIC’s books.

The main near term catalyst still sits with late stage trials such as Himalayas 1 for rinzimetostat and preparations for enozertinib’s Phase III. The biggest risk remains clinical or safety setbacks in these crowded indications, which could weaken future economics and raise pressure for fresh equity financing on less friendly terms.

In this context, the Cancer Research UK agreement around ORIC 259 ties directly into the existing cash story. ORIC ended Q2 2026 with US$388m and has guided that this funds operations into the second half of 2028. Handing early ORIC 259 costs to Cancer Research UK effectively protects more of that pool for rinzimetostat and enozertinib.

This is important if you are watching dilution risk and timing. Large Phase III trials for prostate and lung cancer are expensive, and analysts already flag the possibility of capital raises if timelines slip or data underwhelm. Keeping ORIC 259 off the balance sheet in early development reduces near term strain, while still preserving an option to reclaim rights if Phase 1/2 data justify it.

ORIC Pharmaceuticals’ current analyst narrative points to forecast revenue of US$24.7 million and projected earnings of US$4.3 million by 2029. This is based on a starting point of no revenue and a reported loss of US$140.4 million today, which implies revenue growth from zero and an earnings swing of about US$144.7 million from the current loss to the 2029 consensus profit.

Uncover why ORIC Pharmaceuticals' fair value indicates a 78% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

Another way to look at ORIC Pharmaceuticals is through the bullish catalyst of broader rinzimetostat use. The most optimistic analysts were already penciling in revenue of US$41.5 million and earnings of US$7.2 million by 2029, compared with consensus at US$24.7 million and US$4.3 million. Those views did not factor in the Cancer Research UK funding shift, so you may want to compare several narratives and decide which assumptions feel reasonable to you.

Explore 3 other ORIC Pharmaceuticals fair value estimates, including one that suggests as much as 274% upside from the current price!

The Verdict Is Yours

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

• A great starting point for your ORIC Pharmaceuticals research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• See our latest analysis for ORIC Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate ORIC Pharmaceuticals' overall financial health at a glance.

Looking For More Investment Ideas Beyond ORIC Pharmaceuticals?

Once you have a handle on ORIC Pharmaceuticals, it can help to widen the lens and compare it with other opportunities using the Simply Wall St Screener. That way you are not relying on a single story and can weigh ORIC against businesses with different risk profiles, income potential, and balance sheet strength.

• For investors who want potential mispricing combined with stronger fundamentals, scan a curated set of quality opportunities through the 32 high quality undervalued stocks.
• If resilience matters most to you, filter for businesses with sturdier finances by starting with this list of solid balance sheet and fundamentals (25 results).
• For those who prefer to keep risk in tighter check while still hunting for upside, sift through a 32 resilient stocks with low risk scores that could offer a smoother ride.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com